Early clinical investigations of CAR T-cell therapy demonstrate exceptional response rates and deep remissions in select patients with castration-resistant prostate cancer.
The FDA granted Breakthrough Therapy designation to Adaptimmune's affinity-enhanced T-cell therapy targeting NY-ESO for synovial sarcoma, expediting its development.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.